×
About 54,136 results

Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
http://ascopubs.org/doi/abs/10.1200/JCO.18.01489
Stoffel,E.,et al

Jan 9th, 2019 - All patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pa...

Pancreatic Cancer: Screening - Draft Recommendation Statement
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/pancreatic-cancer-screening1

Feb 4th, 2019 - The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. Pancreatic ductal adenocarcinoma (referred to hereafter as pancreatic cancer) is an uncommon cancer with an age-adjusted annual incidence of 12.6 cases per 100,000 person-years. However, the death rate is 10.9 deaths per 100,000 person-years because the prognosis of pancreatic cancer is poor. Although its inci...

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awz099/5481202
Brain Nelson,P.,et al

Apr 29th, 2019 - We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer’s-type...

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
http://www.bloodjournal.org/content/127/20/2391

May 18th, 2016 - The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnos...

The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15731
Cwynarski,K.,et al

Jan 3rd, 2019 - Primary mediastinal B‐cell lymphoma (PMBCL) represents 2–4% of non‐Hodgkin lymphomas and, whilst previously considered to be a subtype of diffuse large B‐cell lymphoma (DLBCL), gene expression profiling data has shown it to be a separate clinicopathological entity with evidence of an overlap with classic Hodgkin lymphoma (Rosenwald et al, 2003; Savage et al, 2003). Furthermore, it is immunophen...

Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors
https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.html

Aug 20th, 2018 - For most types of cancer, determining the stage (extent) of the cancer is very important. The stage is based on the size of the main tumor and how far the cancer has spread. This can be helpful in predicting a person’s outlook and deciding on treatment.

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...

FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
https://www.taihooncology.com/us/newsroom/press-releases/2019-02-25-LON-PM-US-1213-FDA-Approves-Gastric

Feb 24th, 2019 - Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targete...

2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
https://academic.oup.com/asj/article/39/Supplement_1/S3/5304919
Clemens,M.,et al

Jan 30th, 2019 - National Comprehensive Cancer Network (NCCN) guidelines represent the consensus standard of care for diagnosis and management of the majority of known cancers. NCCN guidelines on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) have been recognized by the US Food and Drug Administration and widely advocated by national specialty societies. Consensus guidelines have helped cre...

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors
https://link.springer.com/article/10.1007%2Fs11864-019-0602-0
Janss,A.,et al

Feb 8th, 2019 - Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Medical management of these adults requires understanding the tumor diagnosis and location, the moda...

Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-u...
https://doi.org/10.1200/JCO.2013.53.5831
Journal of Clinical Oncology : Official Journal of the Am... Daugaard G, Gundgaard MG et. al.

Sep 30th, 2014 - To describe treatment results in a large cohort with stage I nonseminoma germ cell cancer (NSGCC) treated in a surveillance program. From January 1, 1984, to December 31, 2007, 1,226 patients with stage I NSGCC, including high-risk patients with vascular invasion, were observed in a surveillance program. The relapse rate after orchiectomy alone was 30.6% at 5 years. Presence of vascular invasio...

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of g...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482737
British Journal of Cancer; Hurt CN, Falk S et. al.

Apr 4th, 2017 - SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine (CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes. Eligibility: histologically proven LAPC ⩽7 cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles: GEM 1000 mg m-2 days 1, 8, 15; CAP 830 mg m-2 days...

Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498358
Clinical Journal of the American Society of Nephrology : ... Patel HD, Pierorazio PM et. al.

May 9th, 2017 - Management strategies for localized renal masses suspicious for renal cell carcinoma include radical nephrectomy, partial nephrectomy, thermal ablation, and active surveillance. Given favorable survival outcomes across strategies, renal preservation is often of paramount concern. To inform clinical decision making, we performed a systematic review and meta-analysis of studies comparing renal fu...

Microwave ablation of malignant renal tumours: intermediate-term results and usefulness...
https://doi.org/10.1007/s12032-017-0948-8
Medical Oncology (Northwood, London, England); Ierardi AM, Puliti A et. al.

Apr 19th, 2017 - The aim of this study was to evaluate intermediate-term results after microwave ablation (MWA) of renal tumours and determine the association of RENAL and modified RENAL (mRENAL) scores with oncological outcomes and complications. In May 2008-September 2014, 58 patients affected by early-stage RCC (renal cell carcinoma; T1a or T1b) were judged unsuitable for surgery and treated with percutaneou...

Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis.
https://doi.org/10.1530/EJE-10-0412
European Journal of Endocrinology; Abiven-Lepage G, Coste J et. al.

Aug 11th, 2010 - Adrenocortical carcinoma (ACC) is a rare, severe disease. Pregnancy-associated ACC has rarely been reported. We wished to evaluate the characteristics and prognosis of ACC diagnosed in patients during pregnancy or in the postpartum period, comparing them with those for ACC diagnosed in nonpregnant women. Clinical presentation, hormonal secretion, staging, survival, and obstetric data are report...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 11th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Comprehensive Cancer Network (NCCN) annually publishes Clinical Practice Guidelines for Non-Hodgkin Lymphomas. For the first time, BIA-ALCL management will...

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with...
https://doi.org/10.1016/S1470-2045(11)70144-9
The Lancet. Oncology; Vitale A, Morales RR et. al.

Jun 20th, 2011 - Allocation of deceased-donor livers to patients with chronic liver failure is improved by prioritising patients by 5-year liver transplantation survival benefit. The Barcelona Clinic Liver Cancer (BCLC) staging has been proposed as the standard means to assess for prognosis of patients with hepatocellular carcinoma. We aimed to create a prediction model linking the BCLC stage of patients with h...

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitone...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513943
Gynecologic Oncology; Tiersten AD, Liu PY et. al.

Jan 13th, 2009 - Intraperitoneal (IP) chemotherapy prolongs survival in optimally reduced ovarian cancer patients. For patients in whom optimal debulking cannot be achieved, one could incorporate IP therapy post-operatively if the cancer was optimally debulked following neoadjuvant chemotherapy. We sought to evaluate overall survival (OS), progression-free survival (PFS), percent of patients optimally debulked ...

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lympho...
https://doi.org/10.1200/JCO.2009.27.3441
Journal of Clinical Oncology : Official Journal of the Am... Phan J, Mazloom A et. al.

Aug 17th, 2010 - The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The role of consolidative radiation therapy (RT) in the setting of R-CHOP chemotherapy is not well reported. This retrospective analysis is an attempt to clarify this role. Subjects were 469 patients with histologically confi...

Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478573
Journal of Clinical Oncology : Official Journal of the Am... Levenback CF, Ali S et. al.

Jul 3rd, 2012 - To determine the safety of sentinel lymph node biopsy as a replacement for inguinal femoral lymphadenectomy in selected women with vulvar cancer. Eligible women had squamous cell carcinoma, at least 1-mm invasion, and tumor size ≥ 2 cm and ≤ 6 cm. The primary tumor was limited to the vulva, and there were no groin lymph nodes that were clinically suggestive of cancer. All women underwent intrao...